Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
Automated microscopy and image analysis
Real-time, label free cell analysis
Nano and micro particle analysis
Accelerate to discover
Back to filter
Show all topics (10)
Related topics
Advances in Leukemia research using shear flow and Bioflux system
May 24, 2022
Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...
In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers
Mar 9, 2022
Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...
Nov 30, 2021
Microfluidics have revolutionized...
Nov 10, 2021
Join our webinar to learn how...
Curiox webinar: Laminar Wash enables single-cell multiomics and cell hashing
Oct 11, 2021
Professor Mats Bemark’s lab at the University of Gothenburg in Sweden studies how the immune system responds to...
Blood-Brain Barrier (BBB) - Pathophysiology in ischemic stroke
Aug 27, 2021
In-depth Understanding of Blood-Brain Barrier (BBB)
Aug 19, 2021
Year after year, the Micro-CT User meeting showcases state-of-the-art applications in both life and material sciences,...
Predicting single-cell gene expression with imaging flow cytometry data and machine learning
Aug 10, 2021
High-content imaging and single-cell genomics are two of the most prominent high-throughput technologies for studying...
Assessment of CAR T Cell killing capacity against solid tumors-Thursday, October 20, 2016, 5 pm CEST
Oct 13, 2016
Nabil Ahmed, M.D., M.P.H. Associate Professor of Pediatrics, Baylor College of Medicine (USA).
Robust CAR design and sensitive yet realistic functional testing will be required in order to improve the efficacy of CAR T cell therapies targeting solid tumors. We have used the xCELLigence Real-Time Cell Analyzer as a high-throughput platform to test multiple CAR components including extracellular domains (including bi-specifics), signaling endo-domains, as well as next-generation CAR T cell products that are inherently resistant to checkpoint blockade. This platform has proven very sensitive to subtle yet longitudinally meaningful differences in CAR design, and has made it possible to evaluate T cell products in a "stress test" that is more representative of early phase trial requirements.
Related technologies: Real-time, label free cell analysis
Get more info
Brand profile
